Search

Displaying results 651 - 660 of 1786 in total
  1. Drug

    Tafamidis

    go.drugbank.com/drugs/DB11644
    ApprovedInvestigational

    [A189717] Tafamidis was granted an EMA market authorisation on 16 November 2011[L6247] and FDA approval on 3 May 2019.[L11280]

  2. Drug

    Tetrabenazine

    go.drugbank.com/drugs/DB04844
    Approved

    FDA approved on August 15, 2008.

  3. Drug

    Calcium carbimide

    go.drugbank.com/drugs/DB09116
    ApprovedWithdrawn

    Calcium carbimide, sold as the citrate salt, is an alcohol-sensitizing agent. Its effects are similar to the drug disulfiram (Antabuse) in that it interferes with the normal metabolism of alcohol by preventing the breakdown of the metabo...

  4. Drug

    Lecanemab

    go.drugbank.com/drugs/DB14580
    ApprovedInvestigational

    [A253962,L44547] On January 6, 2023, lecanemab was granted accelerated approval by the FDA for the treatment of Alzheimer’s Disease.[L44547] It was granted full FDA approval on July 6, 2023.

  5. Drug

    Carbamoylcholine

    go.drugbank.com/drugs/DB00411
    Approved

    Carbamoylcholine was granted FDA approval on 28 September 1972.[L30245]

  6. Drug

    Pinacidil

    go.drugbank.com/drugs/DB06762
    Approved

    This drug has been discontinued by the FDA.

  7. Drug

    Treosulfan

    go.drugbank.com/drugs/DB11678
    ApprovedInvestigational

    [L52245] It was approved by the EMA in June 2019[L16965] and by the FDA in January 2025 for use in combination with [fludarabine].[L52575]

  8. Drug

    Tazemetostat

    go.drugbank.com/drugs/DB12887
    ApprovedInvestigational

    [A190363] Tazemetaostat was granted FDA approval on 23 January 2020.[L11476]

  9. Drug

    Iopodic acid

    go.drugbank.com/drugs/DB09333
    ApprovedWithdrawn

    It was developed and filed to the FDA by the company BRACCO. This drug was approved on March 15, 1962 but it is nowadays discontinued from the FDA and Health Canada.

  10. Drug

    Nusinersen

    go.drugbank.com/drugs/DB13161
    ApprovedInvestigational

    FDA in December, 2016 as Spinraza for the treatment of children and adults with spinal muscular atrophy (SMA). It is adminstrated as direct intrathecal injection.